Stockscreener 앱 받기
137.89
0.49%
-0.68
시간 외 거래:
139.25
1.36
+0.99%
전일 마감가:
$138.57
열려 있는:
$137.59
하루 거래량:
1.83M
Relative Volume:
0.78
시가총액:
$38.94B
수익:
$7.23B
순이익/손실:
$1.41B
주가수익비율:
27.69
EPS:
4.979
순현금흐름:
$1.09B
1주 성능:
+5.86%
1개월 성능:
+1.38%
6개월 성능:
+1.43%
1년 성능:
+14.74%
1일 변동 폭
$136.14
$139.06
1주일 범위
$125.00
$141.95
52주 변동 폭
$108.35
$160.27
애질런트 테크놀로지스 Stock (A) Company Profile
명칭
Agilent Technologies Inc
전화
(408) 345-8886
주소
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
A
Agilent Technologies Inc
|
137.89 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
TMO
Thermo Fisher Scientific Inc
|
559.53 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.20 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
258.03 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
애질런트 테크놀로지스 Stock (A) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 개시 | HSBC Securities | Buy |
| 2026-01-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-12-15 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-12-09 | 개시 | Goldman | Buy |
| 2025-12-02 | 개시 | Morgan Stanley | Overweight |
| 2025-10-08 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-08 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-10 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-04-05 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-05-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | Citigroup | Neutral |
| 2023-05-24 | 재확인 | Credit Suisse | Outperform |
| 2023-05-24 | 재확인 | Evercore ISI | Outperform |
| 2023-05-24 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | 재확인 | Robert W. Baird | Outperform |
| 2023-05-24 | 재확인 | SVB Securities | Outperform |
| 2023-05-24 | 재확인 | Stifel | Hold |
| 2023-05-24 | 재확인 | TD Cowen | Outperform |
| 2023-05-24 | 재확인 | Wells Fargo | Overweight |
| 2023-05-11 | 개시 | Barclays | Equal Weight |
| 2023-01-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2022-07-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | 재확인 | BofA Securities | Buy |
| 2022-02-23 | 재확인 | Citigroup | Buy |
| 2022-02-23 | 재확인 | Cowen | Outperform |
| 2022-02-23 | 재확인 | Evercore ISI | Outperform |
| 2022-02-23 | 재확인 | Stifel | Hold |
| 2022-02-23 | 재확인 | Wells Fargo | Overweight |
| 2021-11-23 | 재확인 | BofA Securities | Buy |
| 2021-11-23 | 재확인 | Cowen | Outperform |
| 2021-11-23 | 재확인 | Stifel | Hold |
| 2021-03-18 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-12-02 | 개시 | Goldman | Buy |
| 2020-11-25 | 업그레이드 | UBS | Neutral → Buy |
| 2020-11-17 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | 개시 | Atlantic Equities | Neutral |
| 2020-08-19 | 재확인 | BofA Securities | Neutral |
| 2020-08-19 | 재확인 | Citigroup | Neutral |
| 2020-08-19 | 재확인 | Jefferies | Buy |
| 2020-08-19 | 재확인 | Robert W. Baird | Outperform |
| 2020-08-19 | 재확인 | SVB Leerink | Outperform |
| 2020-08-19 | 재확인 | Stifel | Hold |
| 2020-08-19 | 재확인 | Wells Fargo | Overweight |
| 2020-02-24 | 다운그레이드 | Needham | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-26 | 재확인 | Needham | Buy |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-07-16 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | 다운그레이드 | Barclays | Overweight → Equal Weight |
모두보기
애질런트 테크놀로지스 주식(A)의 최신 뉴스
Agilent Technologies Inc (A): GF Score of 94 Signals Strong Outp - GuruFocus
Agilent Technologies price driven lower by important resistanceForecast today27-07-2026 - Economies.com
Precision Trading with Agilent Technologies Inc. (A) Risk Zones - Stock Traders Daily
Agilent Technologies stock steadies as investors weigh recent earnings and life-science demand trend - Ad-hoc-news.de
A|Agilent Technologies Inc|Price:138.570|Chg%:-1.185 - TradingKey
Is Agilent Technologies (A) Undervalued Following Its FDA Approval For OPDIVO Companion Diagnostics? - Yahoo Finance UK
Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test - Yahoo Finance
Agilent Technologies Inc (A) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agilent Technologies Inc (A) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Agilent Technologies Inc (A) Institutional Confidence - TradingKey
Agilent Technologies Inc (A) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
What to Expect From Agilent Technologies' Q3 2026 Earnings Report - inkl
A|Agilent Technologies Inc|Price:139.760|Chg%:+6.300 - TradingKey
Agilent Technologies Inc (A) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agilent declares Q2 2026 distribution of R$ 0.44 per unit, payable July 28 - Bitget
A Look at Agilent Technologies Inc (A) After 4.7% Gain -- GF Val - GuruFocus
Agilent Technologies Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Agilent Technologies (A) Secures EU Certification for Key Diagno - GuruFocus
Why Agilent Technologies Shares Are Rising Today - Quiver Quantitative
Agilent Receives EU Certification for Keytruda Companion Diagnostic in Gynecologic Cancers - Moomoo
Agilent stock rises on EU approval for cancer diagnostic By Investing.com - Investing.com South Africa
Agilent stock rises on EU approval for cancer diagnostic - Investing.com
Agilent receives EU approval for ovarian cancer diagnostic test - Investing.com
Agilent receives EU approval for ovarian cancer diagnostic test By Investing.com - Investing.com South Africa
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - Yahoo Finance
Agilent BDR program executes 5-for-1 stock split on ratio adjustment - Bitget
A4881169 Bond Profile — Key Metrics - TradingView
Agilent Technologies (A) Stock Forecast & Analyst Ratings - Moomoo
Agilent stock holds near report levels as earnings metrics stay in view - Ad-hoc-news.de
Agilent Technologies (NYSE:A) Gains Fresh FDA Momentum - Kalkine Media
Agilent Technologies stock trades steady as life sciences demand supports revenue outlook - Ad-hoc-news.de
Michael Buckner Joins Agilent Technologies as Chief Legal Officer - Medical Product Outsourcing
Agilent Technologies stock trades steadily as investors weigh recent earnings and life sciences dema - Ad-hoc-news.de
Agilent increases HALO X-ray Technologies stake - Airports International
HALO X-ray Technologies Ltd announced that it has received funding from Agilent Technologies, Inc., Future Planet Capital, British Business Investments Ltd., Future Planet Capital Limited - marketscreener.com
Agilent Technologies (A) Stock Analysis: Unlocking a 21% Upside Potential with Robust Market Presence - DirectorsTalk Interviews
Agilent Technologies (A) Wells Fargo 20th Annual Healthcare Conference 2025 Summary - Quartr
Agilent Increases Its Investment in HALO X-ray Technologies - Morningstar
Agilent Technologies (A) Wins FDA Approval, Where Does Fair Value Sit Now? - Sahm
Agilent Technologies (A) Q2 2025 earnings summary - Quartr
Agilent Technologies (A) Q1 2026 earnings summary - Quartr
Agilent Technologies stock trades steady as recent earnings and life-science demand underpin valuati - Ad-hoc-news.de
Agilent Technologies (A) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
Agilent Technologies (A) Proxy Filing Summary - Quartr
Agilent Technologies (A) Q4 2025 earnings summary - Quartr
Agilent Technologies stock holds support as results stay in focus - Ad-hoc-news.de
Agilent 1260 Infinity II LC by Agilent Technologies Inc.mid-range workhorse for routine labs - Ad-hoc-news.de
Agilent Technologies Inc (A) Stock Down 3.4% -- Now Undervalued? GF Score: 93/100 - GuruFocus
Agilent Technologies Inc. stock underperforms Friday when compared to competitors - MarketWatch
Agilent Technologies stock extends focus on earnings and valuation - ad-hoc-news.de
Mass Spectrometry Market Size Worth USD 14.09 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
애질런트 테크놀로지스 (A) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
2.48%
자본화:
|
볼륨(24시간):